drugset / Trial / NCT01866709

Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia

NCT01866709

Phase 4 Terminated 32 enrolled ZS Pharma, Inc.
RandomizedParallel-groupTriple-blindSupportive care

Summary

It is hypothesized that SPS is more effective than placebo control (alternative hypothesis) in lowering i-STAT potassium levels in subjects with i-STAT potassium levels between 5.0 - 6.5 mmol/l versus no difference between SPS and placebo control (null hypothesis).

Timeline

Start
2013-05
Primary completion
2013-07
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator sodium polystyrene sulfonate Other / unclassified 15 g Oral

Indications

No indication recorded.